ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint747,212 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyLausanneAvrion Therapeutics SA
Avrion Therapeutics SA Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Avrion Therapeutics SA develops gene therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Its work includes researching ways to protect synapses, advancing therapeutic candidates, and developing technologies to deliver therapeutic gene sequences to targeted cell types in the central nervous system.

AI-generated
Offering

Products & services

Industry:Pharmaceutical company
✓ Offered
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

Avrion Therapeutics SA

3
Precision gene therapies
Precision gene therapies targeting neurological disorders, with a vector platform specific to cell types of the central nervous system and expression limited to the tissues of interest.
Gene therapy development for ALS
Development of therapeutic candidates AVR-001 and AVR-002 for amyotrophic lateral sclerosis, including preclinical studies and preparatory work for clinical trials.
Therapeutic target discovery
Preclinical target discovery platform in partnership with EPFL, using human genetics, humanized Drosophila models, machine vision, and AI-assisted phenotypic screening.
Trust & reputation

ranQ Trust Score of Avrion Therapeutics SA: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 58% · As of November 2026

Avrion Therapeutics SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Avrion Therapeutics SA scores 76.5 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.70.212%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Avrion Therapeutics SA scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Avrion Therapeutics SA scores 25.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.40.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

Avrion Therapeutics SA reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

January 18, 2021Media
Life science start-ups attract experienced board members
startupticker.ch

Knowledge

No knowledge articles yet

Once Avrion Therapeutics SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Avrion Therapeutics SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Avrion Therapeutics SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Avrion Therapeutics SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Rue de Bourg 27
1003 Lausanne

At a glance

Legal form
Corporation
UID
CHE-217.996.344
Founded
2020 · 6 years
Last commercial register change
October 7, 2026
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
  • Full methodology

    Similar companies

    TP
    Tigen Pharma SA
    Lausanne
    RS
    ReproNovo SA
    Lausanne
    NO
    Neurocol Operations Sàrl
    Lausanne
    GM
    Grand Medical Group AG
    Lausanne
    RB
    Remora Biotech SA
    Epalinges
    HT
    Haya Therapeutics SA
    Epalinges
    HS
    HemostOD SA
    St-Sulpice Vd
    NB
    ND BioSciences SA
    Epalinges